Margarida Azevedo, MSc,  —

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

Articles by Margarida Azevedo

Stem Cell Therapy as COPD Treatment Seen to Offer Benefits

Researchers at the Lung Institute detailed the benefits of autologous stem cell therapy in people with chronic obstructive pulmonary disease (COPD), through an analysis of the treatment’s effects in one of the largest cohorts of these patients. The white paper, authored by Dr. Jack Coleman Jr., MD, was titled “Autologous Stem…

COPD, Other Lung Diseases Could Benefit From Malaysia University, Harvard Partnership

A new research collaboration between Harvard University and Malaysia University’s Malaysia Institute for Innovative Nanotechnology (NanoMITe) will focus on developing and improving smart nanoparticles to deliver therapeutic agents to the lungs of patients with chronic obstructive pulmonary disease (COPD), lung cancer, and other lung diseases. The five-year partnership will apply Harvard’s T.H.

New Assessment Reveals that COPD Outcome in Tiotropium/olodaterol Therapy Differs According to Disease Severity

A dossier assessment developed by the German Institute for Quality and Efficiency in Health Care (IQWiG) examined the added benefit of the fixed-dose combination therapy tiotropium plus olodaterol (Spiolto Respimat), approved this year for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. The study compared tiotropium/olodaterol…

Novartis’ Ultibro® Breezhaler® Superior to Seretide® in Reducing COPD Exacerbations

Novartis recently announced that the company’s once-a-day Ultibro® Breezhaler® (indacaterol/glycopyrronium), a dual bronchodilator, has meet its primary endpoint in a Phase 3 clinical trial (FLAME trial), showing superior efficacy when compared to twice-a-day Seretide® (salmeterol/fluticasone) in reducing mild, moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations. The IGNITE Phase…